Sign In
Buy ALVR
$9.81
+0 (+0%)
At Close: Jun 17, 2025
Insider Selling: AlloVir, Inc. (NASDAQ:ALVR) Insider Sells $134,194.24 in Stock
12:16pm, Friday, 19'th Nov 2021 Dakota Financial News
AlloVir, Inc. (NASDAQ:ALVR) insider Ann M. Leen sold 6,122 shares of the stock in a transaction dated Monday, November 15th. The shares were sold at an average price of $21.92, for a total transaction of $134,194.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the []
Insider Selling: AlloVir, Inc. (NASDAQ:ALVR) Insider Sells 14,766 Shares of Stock
11:26am, Friday, 19'th Nov 2021 Dakota Financial News
AlloVir, Inc. (NASDAQ:ALVR) insider Ann M. Leen sold 14,766 shares of the stock in a transaction dated Friday, November 12th. The shares were sold at an average price of $22.30, for a total value of $329,281.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC []
AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
12:53am, Saturday, 02'nd Oct 2021
My readers will get the background on the stem cell transplant issues. I will offer a discussion on the uniqueness that AlloVir offers patients. The outstanding caliber and experience the management t
New York, New York--(Newsfile Corp. - August 26, 2021) - Levi & Korsinsky announces it has commenced an investigation of Avalara, Inc. (NASDAQ: ALVR) concerning possible breaches of fiduciary duty. To
AlloVir Reports Second Quarter 2021 Financial Results
07:00am, Friday, 06'th Aug 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 202
AlloVir: Targeting Infectious Diseases In Stem Cell Transplant Patients
05:58am, Saturday, 24'th Apr 2021
Uses same technology as MRKR, which I covered earlier. Has a later stage and much more successful program in infectious diseases in HSCT patients.
AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference
07:30am, Wednesday, 17'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Glo
U.S. IPO Week Ahead: Diverse 8 IPO Week Features 3 Billion-Dollar Deals
04:35pm, Sunday, 24'th Jan 2021
The US IPO market is expected to remain active in the week ahead with eight IPOs slated to raise $4.6 billion. Street research is expected for Medirom Healthcare Technologies on Monday, 1/25.
AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
01:52pm, Monday, 11'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster pre
AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:30am, Monday, 04'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Hea
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Inves
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS study dem
Preclinical Data Demonstrate Anti-Viral Activity of AlloVir's ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy
11:00am, Saturday, 05'th Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation at the 6
AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting
01:33pm, Wednesday, 04'th Nov 2020
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that suppor
What Insiders Have To Say About This All-Time High - August 2020 Insider Update
09:00am, Saturday, 05'th Sep 2020
Insider activity is very informative to follow up for two reasons: it can help predict future market movements and it can be interesting to find undervalued stocks.
